Celcuity’s FDA approval of Revtorpyk for cancer was widely expected, but the stock reportedly dipped after the approval followed by a delayed launch timing into the end of the quarter. The market response underscores how execution timing—from label rollout to commercial readiness—can matter to investors even when regulatory milestones land as anticipated. For stakeholders watching launch-phase risk, the episode reinforces that near-term trading may track operational timelines as much as the approval itself.